NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Seaport Therapeutics, Inc. (SPTX) Stock Analysis

Seaport Therapeutics, Inc. (SPTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SPTX

$19.73

+$0.45 (+2.33%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SPTX with… →

SPTX Key Statistics

As of Oct 21, 2026
Trading
Open
$19.27
Previous Close
$19.28
Day's Range
18.00–20.13
52-Week Range
14.85–28.38
Volume
134.58K
Valuation
Market Cap
$1.06B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.81
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$74.88M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
53.53M
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
190.33K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Seaport Therapeutics, Inc. (SPTX) has a market capitalization of $1.06B.

In fiscal 2025, SPTX reported revenue of $0.00.

SPTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$74.88M—
2024$0.00−$46.88M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$87.29M−$74.88M—
2024$0.00—−$52.42M−$46.88M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Seaport Therapeutics, Inc. (SPTX) is capitalised at $1.06B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 58.

SPTX last closed at $19.73 on October 21, 2026. That is +$0.45 (+2.33%) against the previous close. Over the past 52 weeks the price has ranged from $14.85 to $28.38. The latest close sits 32.86% above that 52-week low.

Financial Health

In fiscal 2025, Seaport Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $74.88M. Trailing earnings per share are −5.81.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

No dividend is on file for SPTX.

2026 is still running; the total return is −0.55% year to date.

Peer Comparison

Seaport Therapeutics, Inc. (SPTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Seaport Therapeutics, Inc. SPTX $1.06B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Seaport Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.

Visit website →